Andrea Mambrini

Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study.

Giammaria Fiorentini, Camillo Aliberti, Massimo Tilli et al. · PubMed · 2012 · 331 citations

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer

Erica J. Childs, Evelina Mocci, Daniele Campa et al. · Nature Genetics · 2015 · 265 citations · Full text

Pancreatic Cancer, Medicine, Pathology +8

Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21

Mingfeng Zhang, Zhaoming Wang, Ofure Obazee et al. · Oncotarget · 2016 · 110 citations · Full text

Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial

Michele Reni, Stefano Cereda, Michèle Milella et al. · European Journal of Cancer · 2013 · 90 citations

Pancreatic Cancer, Phase Ii, Gastrointestinal Oncology +8